Since cytokines-induced hyperactive inflammatory responses is the main pathology of chronic inflammatory diseases, e.g. chronic obstructive pulmonary disease (COPD), while HDAC3 inhibition is able to attenuate this disease process, HDAC3 has been considered as a potential target to discover drugs that treat chronic inflammatory diseases. Here, HDAC3 is linked to chronic obstructive pulmonary disease.